FORMULATION ARCHITECTURE
The proposed formulation: 5 mg retatrutide + 20 mg thiamine, engineered in layers
Rethiamine is defined by its architecture, not merely by its ingredient list. The two active components are never stored as one ready-mixed liquid. Instead, they occupy two physically distinct lyophilised layers inside a single protected chamber, and they meet the reconstitution vehicle only in the moments before administration.
The proposed formulation
- Retatrutide lower layer
- 5 mg
- Thiamine upper layer
- 20 mg
- Layer architecture
- dual-layer Peptourbillon™
- Platform
- Lyoprester SS™
- Reconstitution
- 0.5 mL P-EARLs™
- Intended final reconstituted volume
- 0.5 mL
- Developer
- Panacea Bio Chem
- Status
- Proprietary research formulation under development
20 mg thiamine—vitamin B1—with the precise pharmaceutical salt and thiamine-equivalent basis to be declared in the final analytical specification.
Lower layer — the retatrutide peptidic layer
The retatrutide-containing peptidic liquid is introduced first and frozen to create the lower layer. Retatrutide is an investigational once-weekly GIP/GLP-1/glucagon triple receptor agonist; placing it as the foundational frozen stratum gives the peptide a defined, protected position within the cake for the entire lyophilisation cycle.
Upper layer — the thiamine layer
A separately prepared supercooled thiamine-containing liquid is subsequently positioned over the frozen retatrutide layer, creating a physically distinct upper layer. The proposed 20 mg inclusion is a Panacea Bio Chem formulation-development strength — it is not presented as an established clinical requirement, and until the formulation specification is locked, the precise pharmaceutical salt and thiamine-equivalent basis remain to be declared in the final analytical specification.
Co-lyophilisation with spatial separation
The two frozen layers are lyophilised together in the same protected chamber while preserving their layered identity. They share the same lyophilisation cycle and the same final cartridge — but they are not stored as a single premixed liquid. Whether that separation survives freezing, drying and storage without interlayer migration is a core question of the analytical development programme.
P-EARLs™ reconstitution logic
The 0.5 mL P-EARLs™ vehicle is being engineered specifically for this dual-layer formulation. Its scientific role is to reconcile or neutralise pH-, pI-, ionic-strength- and solubility-related conflicts during rapid reconstitution, allowing both layers to form one short-lived injectable preparation immediately before use. This is an engineering objective under evaluation — this website does not state that all pH and pI conflicts have already been eliminated.
The seven-step build, end to end
- 1
Retatrutide peptidic liquid introduced
The retatrutide-containing peptidic liquid (PeptidicLiquid approach) enters the protected chamber first.
- 2
Lower layer frozen
Controlled freezing creates the retatrutide lower layer — the foundation of the dual-layer cake.
- 3
Supercooled thiamine layer positioned
A separately prepared supercooled thiamine-containing liquid is placed over the frozen retatrutide layer.
- 4
Both layers frozen, spatially separated
The upper layer freezes into a physically distinct stratum above the retatrutide layer.
- 5
Co-lyophilisation with spatial separation
One lyophilisation cycle, one chamber, two preserved layers — not a premixed liquid at any point.
- 6
0.5 mL P-EARLs™ activation
Only immediately before use does the separate chamber release its 0.5 mL P-EARLs™ vehicle.
- 7
Rapid unified reconstitution
One short-lived injectable preparation at an intended final volume of 0.5 mL, immediately before the single shot.